O
OCTIMET Oncology
Provides differentiation both within the current treatment paradigms and from competitor agents using biomarker defined intelligent patient selection
About OCTIMET Oncology
OCTIMET is a biotechnology company focused on developing highly selective anti-tumor molecules, particularly cMET inhibitors, to treat cancer. The company employs innovative patient selection and pharmacodynamic biomarker-based strategies to enhance the efficacy of its treatments. OCTIMET operates in the oncology market, targeting pharmaceutical companies and healthcare providers as its primary clients. The business model revolves around drug discovery and development, with revenue generated through partnerships, licensing agreements, and eventual drug sales. The company has a robust pipeline, including its lead candidate OMO-1, which has shown promising results in clinical trials. OCTIMET's team comprises seasoned professionals with extensive experience in global pharma and oncology drug development, ensuring a high level of expertise and innovation in their approach.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 55.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Drug Development, Immersive Technologies, Sustainable Development Goals, Biotech and Pharma, Climate Tech, Woman Founder, DT and LS
- Technology
- Virtual Reality
- Business model
- SaaS
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2017 | $12M | $50M | Omnes Capital · V-Bio Ventures · FundPlus | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for OCTIMET Oncology is 260 monthly website visits, down 16.1% over the last three months. OCTIMET Oncology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
OCTIMET Oncology in the Ghent ecosystem
The OCTIMET Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
V-Bio Ventures
FundPlus
Omnes Capital
Other known investors1 additional known investor
Droia Oncology Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OCTIMET Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OCTIMET Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









